KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered ...

KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued ...

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default. ・A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure ...

ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

KALA BIO ( ($KALA) ) just unveiled an announcement. On December 4, 2025, KALA BIO, Inc. entered into a securities purchase agreement with an ...

Investing.com -- Kala Pharmaceuticals Inc (NASDAQ:KALA) stock dropped 6.7% Friday after the company announced the closing of its previously announced registered direct offering that raised ...

Kala Bio shares surged after the biopharmaceutical company said it had named David Lazar as chief executive and board chair, following the investor's purchase of $6 million in stock. Kala shares were ...

ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...

Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting ...